InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,600.00
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.48
(
0.42%
)
Bitcoin
63,488.24
(
-0.80%
)
Post# of 182928
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

crudeoil24

Send PM Follow Ignore
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

crudeoil24

Member Level

Re: None

Thursday, 05/23/2019 7:39:07 AM

Thursday, May 23, 2019 7:39:07 AM

Post# of 182928
TNXP > Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve biodefense, announced today that it has in-licensed a Phase 2 asset, TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution)* for the treatment of cocaine intoxication. TNX-1300 is designated as a breakthrough therapy by the U.S. Food and Drug Administration (FDA).

New York Yankees and Duke Basketball

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up